CRDF News and Press, Cardiff Oncology Inc. From 01/15/21

Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%,&...

Cardiff Oncology (CRDF) drops 9% in premarket after announcing additional data from Phase 1b/2 trial and initial findings from its Expanded Access Program ((EAP)) launched in June 2020, evaluating onvansertib combined with the chemo regimen FOLFIRI and Avastin&#x...

Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program - Of the 12 Phase 1b patients evaluable for efficacy as of the ASCO-GI data cut-off date (November 1, 2020)...

Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board PR Newswire SAN DIEGO , Dec. 21, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with...

Palm Beach, FL – December 17, 2020 – Soft tissue sarcoma (STS) is a rare type of cancer that develops in tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring in the muscles, tissues, and blood vessels that protect, support and surroun...

Many of the best stocks in 2020 were healthcare companies focused on two disease areas: trying to stop the spread of COVID-19 and improving survival rates from deadly diseases. Their scientific achievements have been nothing less than extraordinary. By looking at healthcare companies with m...

This year, investors flocked to companies trying to solve two of today's biggest health problems: COVID-19 and cancer. Players in these fields took the three top spots in 2020 biotech share performance, each surging more than 1,000%. In fact, they weren't only the best performers in biotech...

Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML SAN DIEGO , Dec. 6, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage biotechnology comp...

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...

Cancer patients with K-Ras mutations comprise a large population with bleak prognosis and minimal treatment options. Recent breakthroughs in targeting only a small portion of K-Ras patients have made multibillion-dollar waves in the biotech sector. Despite failures from past compe...